Management Of Venous Thromboembolism: Optimization By Clinical Trials Journal Articles

abstract

• Antithrombotic therapy is mandatory in most patients with venous thrombosis. The results of randomized trials have established the requirement for initial treatment with heparin and have determined the optimal anticoagulant regimen for secondary prophylaxis. Recent studies have demonstrated that low molecular weight heparins, that have improved pharmacologic and pharmacokinetic properties over standard heparin, are effective and safe in the treatment of deep vein thrombosis. Two large randomized clinical trials have shown the feasibility of the outpatient treatment of patients with acute deep vein thrombosis with low molecular weight heparins. Home therapy will result in improved clinical utility of anticoagulant treatment and in cost savings.

authors

• Turpie, Alexander Graham Gri

status

• published 

publication date

• 1996

has subject area

• 1103 Clinical Sciences (FoR)
• Anticoagulants (MeSH)
• Cardiovascular System & Hematology (Science Metrix)
• Clinical Trials as Topic (MeSH)
• Drug Administration Schedule (MeSH)
• Fibrinolytic Agents (MeSH)
• Hemorrhage (MeSH)
• Heparin (MeSH)
• Heparin, Low-Molecular-Weight (MeSH)
• Humans (MeSH)
• Pulmonary Embolism (MeSH)
• Randomized Controlled Trials as Topic (MeSH)
• Thrombolytic Therapy (MeSH)
• Thrombophlebitis (MeSH)
• Warfarin (MeSH)

published in

• Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research  Journal

keywords

• Anticoagulants
• Clinical Trials as Topic
• Drug Administration Schedule
• Fibrinolytic Agents
• Hemorrhage
• Heparin
• Heparin, Low-Molecular-Weight
• Humans
• Pulmonary Embolism
• Randomized Controlled Trials as Topic
• Thrombolytic Therapy
• Thrombophlebitis
• Warfarin

Digital Object Identifier (DOI)

• 10.1159/000217302

PubMed ID

• 8979127

start page

• 220

end page

• 226

volume

• 26

issue

• Suppl. 4